Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus

NCT03059719 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety and tolerability of the medication PB-119 in adults with Type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 36 people

Who can join Ages 18–75 · all sexes

Timeline Started 2015-04 · est. completion 2016-10

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT03059719 ↗

Description as written by the study sponsor.

This is a randomized, opened, positive drug-controlled (Exenatide, Byetta), sequential parallel group, multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of twelve once-weekly subcutaneous doses of PB-119 to subjects with type 2 diabetes mellitus (T2DM).

Treatments tested

Exenatide injection(Byetta) Biologic
PB-119 injection Biologic

Main thing measured	Incidence of treatment-emergent AE (safety and tolerability)
Sponsor	PegBio Co., Ltd.
Conditions studied	Type II Diabetes Mellitus
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03059719 ↗